KH6 Stock Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.30 |
| 52 Week High | US$22.80 |
| 52 Week Low | US$5.40 |
| Beta | 0.081 |
| 1 Month Change | 5.46% |
| 3 Month Change | 2.66% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 116.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| KH6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.5% | -3.2% | 2.0% |
| 1Y | n/a | -25.4% | 5.9% |
Return vs Industry: Insufficient data to determine how KH6 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how KH6 performed against the German Market.
Price Volatility
| KH6 volatility | |
|---|---|
| KH6 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: KH6 has not had significant price volatility in the past 3 months.
Volatility Over Time: KH6's weekly volatility has decreased from 19% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 29 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
| KH6 fundamental statistics | |
|---|---|
| Market cap | €1.79b |
| Earnings (TTM) | -€212.13m |
| Revenue (TTM) | €6.37m |
280.8x
P/S Ratio-8.4x
P/E RatioIs KH6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KH6 income statement (TTM) | |
|---|---|
| Revenue | US$6.86m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.86m |
| Other Expenses | US$235.55m |
| Earnings | -US$228.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,332.64% |
| Debt/Equity Ratio | 0% |
How did KH6 perform over the long term?
See historical performance and comparison